Article

Anti-amyloid antibody equilibrium binding to Aβ aggregates from human Alzheimer disease brain

2025-05-21

Abstract excerpt

<h4>Importance</h4> Anti-amyloid immunotherapy is used to treat Alzheimer disease (AD) with moderate benefits and potentially serious side effects due to amyloid related imaging abnormality with effusions/edema (ARIA-E). Different anti-amyloid antibodies have different in vitro binding characteristics to different synthetic Aβ aggregates, leading to the assumption that they bind different species in the human br...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 16b3bcf8-dba3-5d26-9ffb-7978fe1ec1c6
DOI: 10.1101/2025.05.20.654902

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Anti-amyloid antibody equilibrium binding to Aβ aggregates from human Alzheimer disease brainDOI 10.1101/2025.05.20.654902Read

Aggregation-Dependent Epitope Sequence and Modification Fingerprints of Anti-Aβ AntibodiesSemantic proximity Read

FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer’s Disease: Where Are We Now?Semantic proximity Read

Distinct serum anti-Aβ antibody patterns in hemorrhagic and inflammatory cerebral amyloid angiopathy manifestationsSemantic proximity Read

Real-World Characterization of Amyloid-Related Imaging Abnormalities (ARIA) in Lecanemab Treatment at an Academic Health SystemSemantic proximity Read

Real-world experience with lecanemab therapy for Alzheimer’s disease in the Intermountain WestSemantic proximity Read

Molecular mechanisms underlying amyloid lowering by aducanumab: differential and comparative effects of sex and IgG reveal the post-treatment disease brainSemantic proximity Read

Fatal Iatrogenic Cerebral Amyloid-Related Encephalitis in a patient treated with lecanemab for Alzheimer’s disease: neuroimaging and neuropathologySemantic proximity Read

Fatal Iatrogenic Cerebral Amyloid-Related Encephalitis in a patient treated with lecanemab for Alzheimer’s disease: neuroimaging and neuropathology.Semantic proximity Read

Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer’s disease to individuals with MCI or early AD in the general populationSemantic proximity Read

Structure of Crenezumab Complex with Aβ Shows Loss of β-HairpinSemantic proximity Read

Lecanemab binds to transgenic mouse model-derived amyloid-β fibril structures resembling Alzheimer’s disease type-I, type-II and Arctic foldsSemantic proximity Read

Anti-amyloid antibody effects on Aβ-42 protein aggregates profiled using nanospectroscopySemantic proximity Read